Brain Tumors

A brain tumor is an abnormal mass of cells growing within or around the brain. Unlike most cells in the body, tumor cells divide without normal controls, accumulating into a mass that disrupts the surrounding tissue. Because the brain is enclosed within the rigid skull, even a non-cancerous growth can compress critical structures, disrupt electrical signaling, and impair functions ranging from language and memory to movement and personality.

Primary vs. Secondary Brain Tumors

Brain tumors are broadly divided into two categories based on their origin. Primary brain tumors begin in the brain or its immediate surroundings — including the meninges (the protective membranes), cranial nerves, the pituitary gland, and the pineal gland. They arise from glial cells, neurons, or supportive tissue within the central nervous system itself. According to the CBTRUS Statistical Report (Ostrom et al., 2020), approximately 87,240 primary brain and other CNS tumors are diagnosed in the United States each year, of which roughly one-third are malignant.

Secondary brain tumors — also called brain metastases — originate elsewhere in the body and spread (metastasize) to the brain through the bloodstream. They are far more common than primary tumors, occurring in 10–30% of all adult cancer patients. The most frequent sources are lung, breast, colon, kidney, and melanoma cancers. Secondary tumors can be single or multiple, and their prognosis depends heavily on the primary cancer type, extent of systemic disease, and the patient's overall performance status.

Benign vs. Malignant Tumors

The distinction between benign (non-cancerous) and malignant (cancerous) tumors is critical, though in the brain this line is more nuanced than elsewhere in the body. A malignant tumor contains cells that are disorganized, divide rapidly, invade surrounding tissue, and may spread to other parts of the nervous system. These tumors are life-threatening both because of their local destruction and their resistance to treatment. A benign tumor, by contrast, has well-defined borders, grows slowly, and does not invade adjacent tissue or metastasize. However, even a benign brain tumor can be dangerous — or even fatal — if it grows in a location that controls vital functions such as breathing, heart rate, or consciousness. A meningioma pressing on the brainstem, for example, may be histologically benign yet life-threatening.

WHO Grading System: Grades I–IV

The World Health Organization (WHO) Classification of Tumors of the Central Nervous System (2021 edition) assigns grades based on tumor aggressiveness, growth rate, and expected clinical behavior. This grading system — updated significantly in 2021 to incorporate molecular markers — informs both prognosis and treatment planning.

• Grade I: Slow-growing, well-differentiated, and typically amenable to surgical cure. Cells appear nearly normal under the microscope. Pilocytic astrocytoma is a classic example, often diagnosed in children and young adults. Prognosis is generally excellent with complete resection.
• Grade II: Relatively slow-growing but with the potential to recur and progress to higher grades over time. Cells show mild abnormalities. Diffuse astrocytoma and oligodendroglioma are common Grade II tumors. Patients may survive many years, though the tumor frequently evolves to a more aggressive form.
• Grade III: Actively malignant. Cells divide rapidly and invade surrounding brain tissue. Anaplastic astrocytoma and anaplastic oligodendroglioma fall here. Treatment typically requires radiation and chemotherapy in addition to surgery. Prognosis is significantly worse than lower-grade tumors.
• Grade IV: Highly aggressive and rapidly growing. The most common and deadliest primary brain tumor — glioblastoma multiforme (GBM) — is Grade IV. These tumors have extensive necrosis (tissue death), abnormal blood vessels, and cells that are highly resistant to treatment. Median survival for GBM remains approximately 14–16 months with optimal therapy, though molecular subgroups exhibit different trajectories.

Common Tumor Types

Gliomas are the most common primary brain tumors, arising from glial cells — the supportive cells of the brain. The glial cell family includes astrocytes, oligodendrocytes, and ependymal cells, and tumors named for each (astrocytomas, oligodendrogliomas, ependymomas) exhibit distinct behaviors, molecular profiles, and treatment responses. Gliomas collectively account for about 80% of all malignant brain tumors in adults.

Glioblastoma multiforme (GBM) is the most aggressive glioma and the most common malignant primary brain tumor in adults, accounting for approximately 14.3% of all brain tumors. The landmark Stupp et al. trial (NEJM, 2005) established the standard of care: maximal surgical resection followed by concurrent radiation therapy and temozolomide chemotherapy, then adjuvant temozolomide. Despite this protocol, median overall survival remains approximately 14–16 months, and the 5-year survival rate is under 10%. Key molecular markers — particularly MGMT promoter methylation and IDH mutation status — have transformed how oncologists classify and prognosticate glioblastoma.

Meningiomas arise from the meninges — the three-layered membrane system (dura mater, arachnoid, and pia mater) that encases the brain and spinal cord. They are the most common primary brain tumor overall, comprising roughly 37% of all primary brain tumors, and are more common in women than men. Most meningiomas are Grade I (benign) and grow slowly over years or decades. They frequently become symptomatic only when they compress adjacent structures, at which point surgical resection can be curative. However, atypical (Grade II) and anaplastic (Grade III) meningiomas recur more frequently and carry a worse prognosis.

Oligodendrogliomas arise from oligodendrocytes and are characterized by the co-deletion of chromosomes 1p and 19q — a genetic hallmark that predicts better response to chemotherapy (PCV regimen: procarbazine, lomustine, and vincristine) and longer overall survival compared to other gliomas. Ependymomas originate from ependymal cells lining the ventricles and are more common in children, often in the posterior fossa. Medulloblastomas are highly malignant tumors of the cerebellum, predominantly affecting children, and are the most common pediatric malignant brain tumor. Acoustic neuromas (vestibular schwannomas) are benign tumors of the vestibulocochlear nerve, causing progressive hearing loss and tinnitus.

Pediatric Brain Tumors

Brain tumors are the most common solid tumor in children and the leading cause of cancer-related death in the pediatric population. They differ meaningfully from adult brain tumors — not just in the types that occur, but in their biology, molecular drivers, location, and response to treatment. A diagnosis in a child or adolescent carries unique considerations around the developing brain, the long-term effects of treatment on cognition and growth, and the profound impact on the entire family.

Juvenile Pilocytic Astrocytoma (JPA) is the most common brain tumor in children, accounting for approximately 17% of all pediatric CNS tumors. It is a Grade I glioma arising from astrocytes, most often in the cerebellum, optic pathway, hypothalamus, or brainstem. JPA is defined at the molecular level by a characteristic BRAF–KIAA1549 gene fusion (present in over 70% of cases), which drives aberrant activation of the MAPK/ERK signaling pathway. This fusion is now both a diagnostic marker and an emerging therapeutic target: BRAF inhibitors (dabrafenib) and MEK inhibitors (trametinib) have shown clinical benefit in BRAF-fusion–positive pediatric low-grade gliomas that are not amenable to surgery. The prognosis for JPA with complete surgical resection is excellent, with 10-year survival rates exceeding 90%. Because of this favorable biology, the tumor earned its own WHO classification as a distinct entity separate from diffuse astrocytomas, reinforcing that its molecular identity — not just its appearance under the microscope — defines its behavior.

Children with JPA of the optic pathway — often associated with neurofibromatosis type 1 (NF1) — may present with progressive visual loss, proptosis, or precocious puberty if the hypothalamus is involved. Cerebellar JPA typically causes ataxia, headache, nausea, and vomiting from obstructive hydrocephalus. While surgery alone can be curative when the tumor is fully accessible, incompletely resected or recurrent tumors in young children may be managed with chemotherapy to avoid or delay radiation, given the severe long-term cognitive effects of cranial irradiation on the developing brain.

Medulloblastoma is the most common malignant brain tumor in children, arising in the cerebellum or fourth ventricle. It is a primitive neuroectodermal tumor (PNET) that grows rapidly, tends to seed the CSF, and can spread throughout the neuraxis. Historically classified by histology alone, medulloblastoma is now recognized as four biologically and clinically distinct molecular subgroups: WNT, SHH, Group 3, and Group 4 (Taylor et al., Acta Neuropathologica, 2012). WNT-subgroup tumors — driven by mutations activating the Wingless/Wnt pathway — carry the best prognosis (5-year survival rates exceeding 90%) and are being studied in trials seeking to de-escalate treatment to reduce long-term side effects. SHH-subgroup tumors are driven by Hedgehog pathway activation and include tumors with PTCH1, SMO, or SUFU mutations, with vismodegib (a Smoothened inhibitor) showing activity in adults. Group 3 tumors carry the worst prognosis and are often associated with MYC amplification. Treatment for medulloblastoma includes maximal surgical resection, craniospinal irradiation (CSI), and adjuvant platinum-based chemotherapy — a combination that, while effective, carries significant risks of cognitive impairment, endocrine dysfunction, hearing loss, and secondary malignancies.

Diffuse Intrinsic Pontine Glioma (DIPG) — now formally designated diffuse midline glioma, H3 K27-altered in the 2021 WHO classification — is among the most devastating diagnoses in all of pediatric oncology. It arises in the pons, the portion of the brainstem responsible for breathing, swallowing, facial movement, and eye control, and infiltrates so diffusely that surgical resection is not possible. DIPG accounts for approximately 10–15% of all pediatric brain tumors and occurs most frequently in children aged 5–10 years. The discovery that over 80% of DIPG tumors harbor a mutation in the histone H3 gene — specifically the H3 K27M substitution — was a watershed moment, described by Mackay et al. in Cancer Cell (2017) and fundamentally reshaping understanding of the tumor's epigenetic dysregulation. Despite this insight, median survival remains only 9–11 months from diagnosis. Radiation therapy (54 Gy in 30 fractions) provides temporary neurological improvement in most patients but does not alter the course of the disease. Numerous clinical trials — including ONC201 (which targets H3K27M-mutant tumors), convection-enhanced delivery (CED) of chemotherapy directly into the brainstem, and CAR-T cell approaches — are actively underway, representing the best current hope for this disease.

Craniopharyngioma is a benign (typically WHO Grade I) tumor arising near the pituitary stalk and hypothalamus from remnants of Rathke's pouch. Although histologically benign, its location makes it one of the most challenging tumors in pediatric neurosurgery. It can compress the pituitary gland, optic chiasm, and hypothalamus — leading to complex constellations of visual loss (classically bitemporal hemianopia), growth hormone deficiency, hypothyroidism, diabetes insipidus, obesity from hypothalamic damage, and neurocognitive impairment. Two histological variants exist: adamantinomatous (more common in children, CTNNB1-mutant) and papillary (more common in adults, BRAF V600E–mutant). The latter is now a target for BRAF/MEK inhibitor combination therapy. Surgery and radiation are the primary treatment modalities, but the neurobehavioral and endocrine consequences of treatment can be as debilitating as the tumor itself, requiring lifelong hormonal replacement and multidisciplinary follow-up.

Atypical Teratoid/Rhabdoid Tumor (ATRT) is a rare but highly aggressive embryonal tumor predominantly affecting infants and young children under age 3. It is defined by inactivation of the SMARCB1 (INI1) gene — a tumor suppressor that regulates chromatin remodeling — and this molecular hallmark distinguishes ATRT from medulloblastoma and other embryonal tumors, with which it was historically confused. ATRT can occur anywhere in the CNS and frequently disseminates through the CSF at diagnosis. Prognosis is poor despite intensive multimodal therapy, with median survival typically under 12 months in infants; older children with localized disease treated aggressively fare somewhat better. Emerging therapies targeting the SWI/SNF chromatin remodeling complex disrupted by SMARCB1 loss are under active investigation.

Ependymoma in the pediatric context most commonly arises in the posterior fossa (fourth ventricle) and is the third most common malignant brain tumor in children. Unlike in adults, pediatric posterior fossa ependymomas are now understood as two distinct molecular groups: EPN_PFA (posterior fossa group A), which affects younger children, often lacks genetic copy number changes, and carries a significantly worse prognosis; and EPN_PFB (posterior fossa group B), which occurs in older children and adolescents and has a more favorable outcome. Supratentorial ependymomas in children frequently harbor RELA or YAP1 fusions, which now carry prognostic significance. Treatment involves maximal surgical resection followed by focal radiation. Chemotherapy has limited proven benefit in ependymoma but is often used in very young children to delay irradiation.

How Tumor Location Shapes Symptoms

One of the most important — and often underappreciated — aspects of brain tumors is that their symptoms are determined almost entirely by where they grow. The same tumor type in two different locations may produce completely different clinical pictures. Understanding the brain's functional geography helps patients and families interpret symptoms and communicate more precisely with their medical teams.

Frontal Lobe: The frontal lobe governs executive function, personality, impulse control, social judgment, planning, problem-solving, and voluntary motor control. Tumors here are frequently among the most difficult for families to recognize because the changes may be behavioral rather than physical. Patients may become uncharacteristically irritable, impulsive, inappropriate, or apathetic — changes that are sometimes attributed to depression, stress, or "personality shift" long before a tumor is discovered. If the tumor involves the primary motor cortex (precentral gyrus), weakness or paralysis of the contralateral (opposite-side) arm or leg may result. Broca's area, responsible for speech production, sits in the dominant frontal lobe, and its involvement can cause expressive aphasia — the patient knows what they want to say but cannot produce the words.

Temporal Lobe: The temporal lobe processes auditory information, is essential for memory formation (via the hippocampus), and — on the dominant side — houses Wernicke's area, which is critical for language comprehension. Tumors in the temporal lobe commonly cause complex partial seizures, which can include unusual sensations, repetitive movements, déjà vu, olfactory hallucinations (smelling things that aren't there), and brief episodes of altered awareness. Memory deficits are also common, particularly difficulty forming new memories. Dominant temporal lobe involvement may cause receptive aphasia — the patient can speak but has difficulty understanding language. Mood disturbances and psychiatric symptoms, including psychosis-like features, can also occur.

Parietal Lobe: The parietal lobe integrates sensory information, processes spatial awareness, and plays a key role in reading, writing, and arithmetic. Tumors here can cause loss of sensation or abnormal sensations (tingling, numbness) on the opposite side of the body, difficulty navigating space, problems with reading (alexia) or writing (agraphia), and a condition called hemispatial neglect — where the patient fails to attend to one half of their visual world, even if vision itself is intact. Apraxia (difficulty performing purposeful movements despite normal motor function) and difficulty with calculation (dyscalculia) are also hallmarks.

Occipital Lobe: The occipital lobe is dedicated to visual processing. Tumors in this area typically cause visual field deficits — a loss of vision in part of the visual field (hemianopia or quadrantanopia) — visual hallucinations, difficulty recognizing objects or faces (visual agnosia), and distorted visual perception. Because vision problems may develop gradually, many patients do not notice or attribute them to other causes, such as aging or eye strain.

Cerebellum: The cerebellum coordinates movement, balance, and fine motor control. Tumors in this region produce a characteristic constellation of symptoms: ataxia (loss of coordination, stumbling gait), dysmetria (inability to judge distances and control the range of movement — reaching past an object, for example), nystagmus (involuntary rhythmic eye movements), and dysarthria (slurred, irregular speech due to uncoordinated speech muscle control). These symptoms can be mistaken for intoxication. Tumors in the posterior fossa (which includes the cerebellum) also frequently obstruct cerebrospinal fluid flow, causing hydrocephalus (abnormal fluid accumulation), dramatically elevated intracranial pressure, and severe headaches.

Brainstem: The brainstem — comprising the midbrain, pons, and medulla oblongata — controls most of the body's automatic life-sustaining functions: breathing, heart rate, blood pressure, swallowing, and consciousness. It also houses the nuclei of most cranial nerves. Brainstem tumors (including the devastating diffuse intrinsic pontine glioma, or DIPG, primarily in children) can cause double vision (diplopia), facial weakness or numbness, difficulty swallowing (dysphagia), unilateral limb weakness, and in advanced disease, respiratory compromise. Because of their location deep within critical structures, brainstem tumors are often inoperable, making them among the most devastating.

General Symptoms Across Tumor Types

Certain symptoms are common across many tumor types and locations because they reflect the general effect of increased intracranial pressure rather than focal brain disruption. Headaches are the most frequently reported symptom, occurring in approximately 50–60% of patients, and classically are worst in the morning, improve during the day, and are aggravated by coughing, sneezing, or bending forward. However, the popular notion that brain tumor headaches are always severe and sudden is misleading — many are dull, persistent, and easy to dismiss.

Seizures occur in 20–40% of patients and are often the presenting symptom for many lower-grade tumors. They may be focal (affecting one part of the body) or generalized (involving the entire brain). A first seizure in an adult with no prior history warrants urgent neuroimaging. Cognitive changes — including difficulty concentrating, memory problems, mental slowing, and confusion — are common and often predate diagnosis by months. Nausea, vomiting (especially projectile), and visual changes (blurring, double vision, or visual field loss) are additional hallmarks of elevated intracranial pressure.

Leptomeningeal Disease (Leptomeningeal Spread)

Leptomeningeal disease (LMD) — also called leptomeningeal carcinomatosis or neoplastic meningitis — occurs when cancer cells spread to the leptomeninges: the two innermost layers of the meninges (arachnoid and pia mater) and the cerebrospinal fluid (CSF) that circulates between them. Cancer cells that gain access to the CSF can disseminate widely throughout the neuraxis, coating the brain surface, spinal cord, and cranial and spinal nerve roots. LMD occurs in approximately 5–8% of patients with solid tumors and is increasingly recognized as cancers live longer due to improved systemic therapies.

The symptoms of LMD reflect multi-focal neurological involvement and can be alarmingly diverse and confusing. Common presentations include persistent headache (often severe and positional), neck stiffness, nausea, cranial nerve palsies (double vision, facial weakness, hearing loss, difficulty swallowing), radiculopathy (radiating pain or weakness in the arms or legs from spinal nerve root involvement), limb weakness, bowel and bladder dysfunction, and progressive cognitive decline. The breadth of symptoms — spanning the brain, cranial nerves, and spinal cord simultaneously — is a distinctive clue. Critically, LMD is frequently misdiagnosed or significantly delayed.

What it is often confused for: Because LMD can present with headache, nausea, neck pain, and cognitive changes, it is frequently mistaken for viral meningitis, tension headache, migraine, cervical spine disease, anxiety, or simple disease progression at a primary site. The absence of fever distinguishes it from infectious meningitis in most cases, but the diagnosis remains elusive until neuroimaging and lumbar puncture are performed. MRI of the full brain and spine with gadolinium contrast is essential, and CSF cytology — the examination of CSF for malignant cells — remains the gold standard for diagnosis, though its sensitivity is only 45–50% on a single sample and improves with repeat sampling.

Prognosis: LMD carries a grim prognosis. Without treatment, survival is typically measured in weeks. With treatment, median survival ranges from 2–4 months for most solid tumors, though some hematological malignancies and breast cancer subtypes with effective targeted therapies fare somewhat better. Treatment options include intrathecal (directly into the CSF) chemotherapy via lumbar puncture or an Ommaya reservoir, systemic chemotherapy with CSF penetration, and craniospinal or focal radiation. Quality of life and neurological stabilization are primary goals. As reviewed by Le Rhun et al. in Cancer Treatment Reviews (2017), novel liquid biopsy techniques using cell-free DNA in CSF offer promising avenues for earlier detection and treatment monitoring.

Diagnosis

The diagnostic workup for a suspected brain tumor begins with a thorough neurological examination, followed by advanced neuroimaging. Magnetic Resonance Imaging (MRI) with and without gadolinium contrast is the preferred study: it offers superior soft-tissue resolution compared to CT, delineates tumor borders with high precision, identifies associated edema and mass effect, and reveals whether a lesion enhances with contrast — a sign of blood-brain barrier disruption often associated with higher-grade tumors. Functional MRI (fMRI) and diffusion tensor imaging (DTI) are used pre-operatively to map eloquent cortex (critical language and motor areas) and white matter tracts, helping surgeons plan resection with maximal safety margins.

CT (Computed Tomography) scanning is faster and more widely available, making it the go-to emergency study when symptoms are acute or a patient cannot undergo MRI. CT reliably identifies hemorrhage, hydrocephalus, large mass lesions, and calcifications (a hallmark of some tumor types), but lacks the resolution and multi-planar capability of MRI. MR Spectroscopy (MRS) measures the metabolic fingerprint of a lesion, helping distinguish tumor from radiation necrosis, abscess, or other pathologies. Positron Emission Tomography (PET) scanning, particularly with amino acid tracers such as 18F-FET or 11C-MET, provides metabolic information complementary to MRI and is used in recurrence assessment.

Biopsy and molecular profiling are essential. A tissue diagnosis via stereotactic biopsy or open surgical resection provides the histological and molecular information required for definitive diagnosis and treatment planning. The 2021 WHO classification places enormous weight on molecular markers: IDH mutation status, 1p/19q co-deletion, MGMT promoter methylation, TERT promoter mutation, CDKN2A/B homozygous deletion, and EGFR amplification, among others, are now integrated into the tumor's formal diagnosis. In some cases, liquid biopsy — analyzing circulating tumor DNA in blood or CSF — offers a less invasive option for monitoring disease and detecting recurrence.

Treatment Options

Treatment is tailored to tumor type, grade, location, molecular profile, and the patient's age and neurological status. The goals span a spectrum from curative intent (Grade I tumors amenable to complete resection) to life prolongation and quality-of-life preservation (high-grade gliomas and brain metastases). A multidisciplinary tumor board — comprising neurosurgery, neuro-oncology, radiation oncology, neuropathology, and neuropsychology — guides management at major cancer centers.

Surgical Resection (Craniotomy): The cornerstone of treatment for most resectable brain tumors is surgery. A craniotomy — the surgical removal of a section of skull to access the brain — allows the neurosurgeon to remove as much tumor tissue as safely possible. The extent of resection (EOR) is one of the most significant determinants of survival in glioma, with gross total resection (GTR) associated with longer progression-free and overall survival compared to subtotal resection. Awake craniotomy techniques — where the patient is kept conscious during portions of surgery to allow real-time speech and motor mapping — enable resection of tumors in eloquent areas that would otherwise be deemed inoperable. As reviewed in Sanai & Berger's comprehensive analysis (Neurosurgery, 2017), intraoperative MRI, fluorescence-guided surgery (5-ALA), and neuronavigation have dramatically improved the safety and completeness of tumor removal.

Radiation Therapy: Radiation is a critical component of treatment for most malignant brain tumors and many benign recurrent tumors. Standard external beam radiation therapy (EBRT) delivers fractionated radiation over 4–6 weeks, typically following surgery for high-grade gliomas. Stereotactic radiosurgery (SRS) — including Gamma Knife, CyberKnife, and LINAC-based systems — delivers a precisely targeted high dose of radiation to a small lesion in a single session or a few sessions, minimizing dose to surrounding tissue. It is particularly effective for brain metastases (1–4 lesions), acoustic neuromas, and meningiomas. Proton therapy offers dosimetric advantages over conventional photon radiation: because protons deposit the majority of their energy at a defined depth (the Bragg peak) and virtually none beyond it, surrounding normal brain tissue receives a significantly lower dose. As reviewed by Indelicato et al. (International Journal of Radiation Oncology, 2019), proton therapy is particularly beneficial for pediatric tumors and skull base tumors near critical structures, reducing the risk of long-term neurocognitive sequelae.

Chemotherapy: Temozolomide (TMZ), an oral alkylating agent, is the standard chemotherapy for GBM, administered concurrently with radiation and then in 6 adjuvant cycles. Tumor Treating Fields (TTFields) — delivered via a wearable scalp device (Optune) that generates alternating electric fields disrupting tumor cell division — have been approved as an adjunct to temozolomide for newly diagnosed GBM following the EF-14 trial (Stupp et al., JAMA 2015). For oligodendrogliomas with 1p/19q co-deletion, the PCV regimen (procarbazine, lomustine, vincristine) combined with radiation has shown significant survival benefit. Bevacizumab (Avastin), an anti-VEGF antibody, is used in recurrent GBM to reduce tumor vascularity and improve quality of life, though it has not demonstrated an overall survival benefit.

Targeted Therapy and Immunotherapy: Molecular profiling has opened the door to targeted therapies. Ivosidenib and olutasidenib target mutant IDH1 enzymes in IDH-mutant gliomas. Larotrectinib targets NTRK fusions, which occur in a small subset of gliomas. Immune checkpoint inhibitors (pembrolizumab, nivolumab) have shown modest results in GBM to date, but ongoing trials in molecularly selected populations (e.g., mismatch repair deficient tumors) and novel delivery strategies — including local delivery to bypass the blood-brain barrier — represent active areas of investigation. CAR-T cell therapy and cancer vaccines targeting tumor-specific antigens (such as EGFRvIII-targeted vaccines) are in clinical trials.

Prognostic Factors

Prognosis in brain tumors is multi-factorial. The most powerful prognostic variables in adult gliomas include: WHO grade; IDH mutation status (IDH-mutant tumors behave far more favorably than IDH-wildtype at the same histological grade); MGMT promoter methylation (methylated tumors respond better to temozolomide); 1p/19q co-deletion in oligodendrogliomas; extent of surgical resection; patient age (younger patients fare better); and Karnofsky Performance Status (KPS), a measure of functional capacity. For brain metastases, the Graded Prognostic Assessment (GPA) score — which incorporates primary cancer type, number of metastases, KPS, and age — provides individualized survival estimates. Parsons et al. (Science, 2008) first characterized IDH mutations as a paradigm-shifting prognostic biomarker, fundamentally reshaping how the field classifies and treats diffuse gliomas.

Quality of Life

Quality of life is a central concern in brain tumor care — arguably as important as survival in the context of diseases that frequently carry a poor prognosis. Treatment side effects can be profound: surgery may cause new neurological deficits; radiation can produce fatigue, alopecia, and over months to years, radiation necrosis or cognitive decline; corticosteroids (used to manage edema) cause insomnia, weight gain, mood swings, and immune suppression; and chemotherapy contributes to fatigue, myelosuppression, and nausea. Cognitive impairment — affecting memory, processing speed, and executive function — is among the most distressing and persistent consequences.

Multidisciplinary supportive care — including neuropsychological rehabilitation, physical and occupational therapy, speech-language therapy, palliative care integration, and psychological support — is essential and should begin at diagnosis rather than being reserved for end of life. As demonstrated in a landmark study by Taphoorn et al. in The Lancet Oncology (2018), patients who receive early integrated palliative care alongside standard oncology treatment demonstrate better symptom management, preserved independence longer, and improved quality-of-life scores — underscoring that comfort and curative care are not in opposition.

For young adults — the demographic at the heart of the reBRAINed initiative — the impact of a brain tumor reverberates through education, employment, relationships, fertility, and identity in ways that differ meaningfully from older populations. Neuropsychological assessment and cognitive rehabilitation programs, fertility preservation counseling prior to chemotherapy or radiation, peer support networks, and transition planning back into academic or professional life are all components of comprehensive care.

Sources & Further Reading

• Brain and Spinal Cord Tumors Overview — National Cancer Institute (NCI) — Comprehensive patient and clinical information on brain tumor types, staging, and treatment from the U.S. government's primary cancer research agency.
• American Brain Tumor Association (ABTA) — Patient resources, treatment information, clinical trial listings, and support programs for brain tumor patients and families.
• National Brain Tumor Society — Advocacy, research funding, and practical resources including a clinical trial finder and nurse navigation support.
• CBTRUS Statistical Report — Ostrom QT et al., Neuro-Oncology (2020) — The definitive annual epidemiological report on primary brain and CNS tumors in the United States, published by the Central Brain Tumor Registry of the United States.
• The 2021 WHO Classification of Tumors of the Central Nervous System — Louis DN et al., Neuro-Oncology (2021) — The authoritative molecular-integrated reclassification of all CNS tumors, redefining diagnosis based on both histology and molecular markers.
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma — Stupp R et al., NEJM (2005) — The landmark randomized trial that established the current standard of care for GBM: concurrent radiation and temozolomide chemotherapy.
• Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide for GBM — Stupp R et al., JAMA (2015) — The EF-14 trial demonstrating improved overall survival with TTFields (Optune device) added to standard GBM therapy.
• MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma — Hegi ME et al., NEJM (2005) — Established MGMT promoter methylation as a predictive biomarker for chemotherapy benefit in GBM.
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme — Parsons DW et al., Science (2008) — Seminal paper identifying IDH1 mutations as a major prognostic marker and paradigm-shifting discovery in glioma biology.
• Extent of Resection in Malignant Glioma — Sanai N & Berger MS, Neurosurgery (2017) — Comprehensive review of the evidence for maximal safe resection in glioma and outcomes by extent of resection.
• Proton Therapy for Pediatric Brain Tumors — Indelicato DJ et al., International Journal of Radiation Oncology (2019) — Evidence for proton therapy's dosimetric and clinical advantages in pediatric and skull base brain tumor treatment.
• Leptomeningeal Metastases: Diagnosis and Treatment — Le Rhun E et al., Cancer Treatment Reviews (2017) — Comprehensive review of leptomeningeal carcinomatosis, including diagnosis, emerging liquid biopsy techniques, and treatment strategies.
• Health-Related Quality of Life in Primary Brain Tumor Patients — Taphoorn MJB et al., The Lancet Oncology (2018) — Evidence for early palliative care integration improving quality-of-life outcomes in brain tumor patients.
• Stereotactic Radiosurgery for Brain Metastases — Sheehan JP et al., Journal of Neurosurgery (2018) — Review of SRS outcomes for brain metastases, including Gamma Knife, LINAC, and CyberKnife modalities.
• Brain Tumor — Symptoms and Causes — Mayo Clinic — Trusted clinical overview of brain tumor presentation, types, risk factors, and diagnosis for patients and families.
• Brain Tumors — Memorial Sloan Kettering Cancer Center — Expert clinical information on brain tumor diagnosis, surgery, radiation, and chemotherapy from one of the world's leading cancer centers.
• UCSF Brain Tumor Center — Clinical resources and research updates from one of the foremost academic brain tumor programs in the United States.
• DIPG Advocacy Group — Resources, research updates, and support for families affected by diffuse intrinsic pontine glioma (DIPG), the most aggressive pediatric brainstem tumor.
• Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene — Jones DT et al., Science (2008) — Discovery of the BRAF–KIAA1549 fusion as the defining molecular event in juvenile pilocytic astrocytoma.
• Molecular Subgroups of Medulloblastoma — Taylor MD et al., Acta Neuropathologica (2012) — Definitive molecular classification of medulloblastoma into four subgroups (WNT, SHH, Group 3, Group 4) with distinct biology, demographics, and prognosis.
• Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and DIPG — Mackay A et al., Cancer Cell (2017) — Landmark molecular characterization of DIPG/diffuse midline glioma, establishing H3 K27M as the defining molecular alteration.
• Pediatric Brain Tumor Foundation — Support, education, and research funding for families affected by pediatric brain tumors, including JPA, medulloblastoma, and DIPG.
• CERN Foundation for Ependymoma Research — Patient resources, clinical trial listings, and research updates dedicated to ependymoma in children and adults.